MX2014015251A - Nanocerios para el tratamiento del estres oxidativo. - Google Patents

Nanocerios para el tratamiento del estres oxidativo.

Info

Publication number
MX2014015251A
MX2014015251A MX2014015251A MX2014015251A MX2014015251A MX 2014015251 A MX2014015251 A MX 2014015251A MX 2014015251 A MX2014015251 A MX 2014015251A MX 2014015251 A MX2014015251 A MX 2014015251A MX 2014015251 A MX2014015251 A MX 2014015251A
Authority
MX
Mexico
Prior art keywords
oxidative stress
cerium oxide
multiple sclerosis
oxide nanoparticles
nanoceria
Prior art date
Application number
MX2014015251A
Other languages
English (en)
Inventor
Kenneth Joseph Reed
Wendi Ann Costanzo
Joseph Samuel Erlichman
Eric Leslie Bell
Original Assignee
Cerion Entpr Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerion Entpr Llc filed Critical Cerion Entpr Llc
Publication of MX2014015251A publication Critical patent/MX2014015251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)

Abstract

Se describe un proceso para la fabricación de nanopartículas de materiales biocompatibles, en donde una mezcla de reacción acuosa que comprende ion ceroso, ácido cítrico y ácido etilendiaminotetraacético en una proporción determinada, un oxidante y el agua se proporciona junto con condiciones de temperatura para formar directamente, sin aislamiento, una dispersión estable de nanopartículas de óxido de cerio. Estas nanopartículas de óxido de cerio biocompatibles se pueden utilizar para prevenir y/o tratar las enfermedades relacionadas con el estrés oxidativo, tales como un derrame cerebral, esclerosis múltiple de recaída/remisión, esclerosis múltiple crónica progresiva, esclerosis lateral amiotrófica, y lesión por reperfusión isquémica.
MX2014015251A 2012-06-13 2013-03-15 Nanocerios para el tratamiento del estres oxidativo. MX2014015251A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261689806P 2012-06-13 2012-06-13
US201261690100P 2012-06-18 2012-06-18
US201261795241P 2012-10-12 2012-10-12
US201261796639P 2012-11-16 2012-11-16
PCT/US2013/032318 WO2013187980A1 (en) 2012-06-13 2013-03-15 Nanoceria for the treatment of oxidative stress

Publications (1)

Publication Number Publication Date
MX2014015251A true MX2014015251A (es) 2015-04-13

Family

ID=48048227

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015251A MX2014015251A (es) 2012-06-13 2013-03-15 Nanocerios para el tratamiento del estres oxidativo.

Country Status (12)

Country Link
US (4) US9034392B2 (es)
EP (1) EP2861212B1 (es)
JP (1) JP6174692B2 (es)
KR (1) KR101990070B1 (es)
CN (1) CN104812375B (es)
AU (1) AU2013274901B2 (es)
CA (1) CA2875206C (es)
DK (1) DK2861212T3 (es)
ES (1) ES2617528T3 (es)
IN (1) IN2014DN10550A (es)
MX (1) MX2014015251A (es)
WO (1) WO2013187980A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10550A (es) 2012-06-13 2015-08-21 Cerion Entpr Llc
US9446070B2 (en) * 2012-06-13 2016-09-20 Cerion, Llc Nanoceria with citric acid additive
AU2014256983B2 (en) 2013-04-25 2018-10-04 Cerion Enterprises, Llc Chelated nanoceria for the treatment of oxidative stress
US10182994B2 (en) * 2014-06-10 2019-01-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nanoparticulate complex of nicotine and cerium oxide and use thereof
BR112017000800A8 (pt) * 2014-07-17 2023-04-25 Biocurity Holdings Inc Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico
JP2018508568A (ja) 2015-01-20 2018-03-29 セリオン，リミティド ライアビリティ カンパニー カタラーゼ様活性を有するｅｄｄｓでキレート化されたナノセリア
KR101765557B1 (ko) 2015-02-27 2017-08-23 서울대학교산학협력단 생흡수성 전자 스텐트
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
EP3380088A4 (en) * 2015-11-25 2019-07-31 The Regents of the University of Colorado, A Body Corporate USE OF MICRO-RNA 146A AND NANOCERIA CONJUGATE TO IMPROVE WOUND HEALING AND PROMOTE TISSUE GENERATION
AU2017384425B2 (en) * 2016-12-21 2023-08-31 Nanobiotix Nanoparticles for use for treating a neuronal disorder
AU2018390163B2 (en) 2017-12-19 2024-05-02 Nanobiotix Nanoparticles for use in enhancing brain performances or in treating stress
HUE068741T2 (hu) 2017-12-19 2025-01-28 Nanobiotix Nanorészecskék idegi zavarok kezelésére
WO2020069292A1 (en) * 2018-09-28 2020-04-02 The Regents Of The University Of Colorado, A Body Corporate Methods for preventing and treating pulmonary inflammation and fibrosis
CN111333098B (zh) * 2018-11-30 2022-04-19 中国科学院大连化学物理研究所 二氧化铈纳米立方块的制备方法
CN109806278B (zh) * 2019-02-01 2021-08-10 浙江大学 磷脂聚乙二醇修饰的超小型氧化铈纳米晶的应用
FR3093640B1 (fr) * 2019-03-15 2021-10-01 Biophytis Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de maladies neuromusculaires
CN109939125B (zh) * 2019-04-22 2021-05-18 南昌大学第二附属医院 一种抗氧化剂及其制备方法与应用
FR3098723B1 (fr) * 2019-07-18 2023-01-13 Bionuclei Traitement ecobiologique des effets secondaires de la radiotherapie.
KR102107760B1 (ko) * 2019-08-28 2020-05-07 한국콜마주식회사 피부 장벽 강화, 피부 보습 및/또는 미세 먼지 차단용 세륨옥사이드 분산액 및 이를 포함하는 화장료 조성물
JP7740020B2 (ja) * 2020-05-27 2025-09-17 東レ株式会社 酸化セリウムのナノ粒子、抗菌剤、抗ウイルス剤および酸化セリウムのナノ粒子の製造方法
CN111773243B (zh) * 2020-07-17 2022-09-23 南京大学 炎症性肠病的药物及其制备方法和用途
CN112007016B (zh) * 2020-09-07 2021-07-23 南京大学 一种纳米缓释制剂及其制备方法和在制备治疗线粒体功能障碍疾病的药物中的应用
CN112494513A (zh) * 2020-12-15 2021-03-16 中国药科大学 一种二氧化铈纳米粒及其制备方法与应用
CN112516294B (zh) * 2020-12-22 2023-04-07 浙江大学 一种氧化铈纳米稳定剂在制备预防过敏性疾病药物中的应用及预防过敏性疾病的药物组合物
CN113546093A (zh) * 2021-07-20 2021-10-26 中国人民解放军陆军军医大学 氧化铈纳米颗粒在制备治疗和预防肾缺血再灌注损伤的药物中的应用
CN113842469B (zh) * 2021-08-25 2024-04-02 中国科学院过程工程研究所 一种囊泡表面原位结晶高催化活性铈纳米晶的递药系统及其制备方法和应用
CN114470326B (zh) * 2021-12-06 2022-09-13 中国人民解放军空军军医大学 一种仿生矿化胶原-糖胺聚糖材料制备方法及其应用
KR102810481B1 (ko) * 2022-01-21 2025-05-19 성균관대학교산학협력단 다발성경화증 치료용 백신
US12521414B2 (en) * 2022-06-08 2026-01-13 National Health Research Institutes Method for preventing or treating urological chronic pelvic pain syndrome
CN116270729A (zh) * 2022-11-09 2023-06-23 西安交通大学医学院第一附属医院 多孔纳米棒状氧化铈在制备治疗特应性皮炎的药物中的应用
CN115737678B (zh) * 2022-11-30 2024-12-20 浙江大学金华研究院 载三苯基膦修饰的氧化铈和全反式维甲酸的脂质体凝胶
CN116180065B (zh) * 2022-12-27 2024-10-08 国科大杭州高等研究院 一种表面改性的镍钛合金材料及其制备方法和应用
CN116036127B (zh) * 2023-01-17 2025-09-23 中国人民解放军陆军军医大学 氧化铈纳米簇在改善慢性肾病中的应用
AU2023424695A1 (en) * 2023-01-18 2025-08-28 Applause Pharma Co., Ltd. Pharmaceutical composition having, as active ingredient, cerium compound that contains trivalent cerium
CN116850147B (zh) * 2023-06-05 2024-05-14 中南大学 Ppc纳米颗粒、其制备方法以及在治疗心肌梗死的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809637B1 (fr) 2000-06-05 2003-01-24 Rhodia Terres Rares Dispersion colloidale d'un compose de cerium ou d'un compose de cerium et d'au moins un autre element choisi parmi les terres rares et des metaux de transition et comprenant un acide amine
JP3768401B2 (ja) 2000-11-24 2006-04-19 Ｎｅｃエレクトロニクス株式会社 化学的機械的研磨用スラリー
JP3586711B2 (ja) 2000-12-27 2004-11-10 独立行政法人物質・材料研究機構 ナノセリア粉末の製造方法
JP3793802B2 (ja) 2001-07-09 2006-07-05 独立行政法人物質・材料研究機構 個々の粒子がナノサイズに分離したセリア粉末の製造法
US7563457B2 (en) 2001-10-02 2009-07-21 The Regents Of The University Of California Nanoparticle assembled hollow spheres
US7534453B1 (en) 2002-09-05 2009-05-19 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticles and use in enhancing cell survivability
KR100486959B1 (ko) * 2003-01-29 2005-05-03 한국화학연구원 나노 크기의 세리아 제조방법
EP1765280A1 (en) 2004-06-28 2007-03-28 Procyte Corporation Methods and compositions for preventing and treating hyperpigmentation of skin
WO2007002662A2 (en) 2005-06-27 2007-01-04 Edward Via Virginia College Of Osteopathic Medicine Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles
WO2008002323A2 (en) 2005-12-23 2008-01-03 Eastman Kodak Company Production of cerium containing metal oxide grains
WO2008030815A2 (en) * 2006-09-05 2008-03-13 Cerion Technology, Inc. Method of preparing cerium dioxide nanoparticles
WO2009012425A2 (en) 2007-07-19 2009-01-22 Logigal Therapeutics, Inc. Compositions including leukotriene antagonists and nsaids and methods of using the same
DE102007062571A1 (de) 2007-12-22 2009-06-25 Evonik Degussa Gmbh Ceroxid und Schichtsilikat enthaltende Dispersion
CN101683999A (zh) * 2008-09-26 2010-03-31 杜小青 纳米二氧化铈制备方法
CN102281945A (zh) * 2008-12-17 2011-12-14 丝润技术有限公司 包含晶格经改造的二氧化铈纳米颗粒的燃料添加剂
US8679344B2 (en) 2008-12-17 2014-03-25 Cerion Technology, Inc. Process for solvent shifting a nanoparticle dispersion
IN2014DN10550A (es) 2012-06-13 2015-08-21 Cerion Entpr Llc

Also Published As

Publication number Publication date
IN2014DN10550A (es) 2015-08-21
JP2015525228A (ja) 2015-09-03
WO2013187980A1 (en) 2013-12-19
US20180250333A1 (en) 2018-09-06
JP6174692B2 (ja) 2017-08-02
US9962406B2 (en) 2018-05-08
CN104812375B (zh) 2017-08-22
EP2861212A1 (en) 2015-04-22
KR101990070B1 (ko) 2019-06-17
AU2013274901A1 (en) 2014-12-18
US20130337083A1 (en) 2013-12-19
AU2013274901B2 (en) 2017-09-14
ES2617528T3 (es) 2017-06-19
US20150231174A1 (en) 2015-08-20
US9533007B2 (en) 2017-01-03
CA2875206C (en) 2020-07-14
KR20150028293A (ko) 2015-03-13
DK2861212T3 (en) 2017-03-06
CA2875206A1 (en) 2013-12-19
CN104812375A (zh) 2015-07-29
US9034392B2 (en) 2015-05-19
US20170100430A1 (en) 2017-04-13
US10729717B2 (en) 2020-08-04
EP2861212B1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
MX2014015251A (es) Nanocerios para el tratamiento del estres oxidativo.
WO2014176487A3 (en) Chelated nanoceria for the treatment of oxidative stress
CA2863964C (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
BR112015015031A2 (pt) processo de glicoconjugação
HK1213552A1 (zh) 经取代的苯化合物
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2013090523A3 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
WO2013158744A3 (en) Nanoparticles of cerium and amino acids
WO2014111876A3 (en) Modulation of mitophagy and use thereof
IN2012DE00497A (es)
WO2011146167A8 (en) Hydroalkylation processes
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
MX350985B (es) Hidrogenación de productos de isohexida para color mejorado.
WO2014016352A3 (en) Process
PH12016500738A1 (en) Formulation for gonadotropins
MX2010009999A (es) Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad.
NZ615623A (en) Chemical composition with hydrogen peroxide and a nanoemulsion of long-chained alcohols
PH12015500322A1 (en) Tris(hetero)arylpyrazoles and use thereof
AU2013367193A8 (en) Wound healing accelerator
MX2016006790A (es) Producto cosmetico con propiedades reparadoras del adn.
EP2594268A4 (en) ANGIOGENIC INHIBITORY COMPOSITION WITH MACROLACTIN A AND A DERIVATIVELY AS ACTIVE SUBSTANCES
AR098023A1 (es) Un proceso para preparar isoxaflutol
WO2014104989A8 (en) Pharmaceutical compositions comprising aripiprazole
BR112013022781A2 (pt) composição de limpeza, artigo, método para a preparação de uma solução estabilizada com um agente tensoativo orgânico e um oxidante e utilização de um componente antioxidante anfifílico para melhorar a estabilidade de um componente tensoativo na presença de um oxidante

Legal Events

Date Code Title Description
FG Grant or registration